HRP20140257T4 - Uporaba ciklesonida za liječenje bolesti dišnih puteva - Google Patents

Uporaba ciklesonida za liječenje bolesti dišnih puteva Download PDF

Info

Publication number
HRP20140257T4
HRP20140257T4 HRP20140257TT HRP20140257T HRP20140257T4 HR P20140257 T4 HRP20140257 T4 HR P20140257T4 HR P20140257T T HRP20140257T T HR P20140257TT HR P20140257 T HRP20140257 T HR P20140257T HR P20140257 T4 HRP20140257 T4 HR P20140257T4
Authority
HR
Croatia
Prior art keywords
use according
ciclesonide
diene
dione
dose
Prior art date
Application number
HRP20140257TT
Other languages
English (en)
Croatian (hr)
Inventor
Thomas Bethke
Renate Engelstaetter
Wilhelm Wurst
Original Assignee
Covis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34312429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140257(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Covis Pharma Gmbh filed Critical Covis Pharma Gmbh
Publication of HRP20140257T1 publication Critical patent/HRP20140257T1/hr
Publication of HRP20140257T4 publication Critical patent/HRP20140257T4/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HRP20140257TT 2003-09-16 2004-09-15 Uporaba ciklesonida za liječenje bolesti dišnih puteva HRP20140257T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50298403P 2003-09-16 2003-09-16
EP04766791.0A EP1670482B2 (en) 2003-09-16 2004-09-15 Use of ciclesonide for the treatment of respiratory diseases
PCT/EP2004/052172 WO2005025578A1 (en) 2003-09-16 2004-09-15 Use of ciclesonide for the treatment of respiratory diseases

Publications (2)

Publication Number Publication Date
HRP20140257T1 HRP20140257T1 (hr) 2014-04-25
HRP20140257T4 true HRP20140257T4 (hr) 2022-11-25

Family

ID=34312429

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140257TT HRP20140257T4 (hr) 2003-09-16 2004-09-15 Uporaba ciklesonida za liječenje bolesti dišnih puteva

Country Status (11)

Country Link
US (4) US8371292B2 (cg-RX-API-DMAC7.html)
EP (1) EP1670482B2 (cg-RX-API-DMAC7.html)
JP (2) JP5618452B2 (cg-RX-API-DMAC7.html)
AU (1) AU2004271744B2 (cg-RX-API-DMAC7.html)
CA (1) CA2538419C (cg-RX-API-DMAC7.html)
DK (1) DK1670482T4 (cg-RX-API-DMAC7.html)
ES (1) ES2452691T5 (cg-RX-API-DMAC7.html)
HR (1) HRP20140257T4 (cg-RX-API-DMAC7.html)
PL (1) PL1670482T5 (cg-RX-API-DMAC7.html)
PT (1) PT1670482E (cg-RX-API-DMAC7.html)
WO (1) WO2005025578A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879833B2 (en) * 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
ES2452691T5 (es) * 2003-09-16 2022-09-14 Covis Pharma Gmbh Uso de ciclesonida para el tratamiento de enfermedades respiratorias
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
EP1720577A2 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
JP2007533706A (ja) * 2004-04-20 2007-11-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
WO2007092574A2 (en) * 2006-02-08 2007-08-16 Sicor, Inc. Crystalline forms of ciclesonide
NZ584876A (en) * 2007-10-25 2012-06-29 Merck Frosst Canada Ltd Inhalation compositions comprising montelukast acid and a pde-4-inhibitor or an inhaled corticosteroid
EP2407476B1 (en) * 2009-03-09 2014-05-07 Mikasa Seiyaku Co,. Ltd. Steroid compound
CA2844944A1 (en) 2011-08-18 2013-02-21 Takeda Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation
AU2013360691B2 (en) 2012-12-21 2018-03-08 Boehringer Ingelheim Vetmedica Gmbh Ciclesonide for the treatment of airway disease in horses
ES2909039T3 (es) 2012-12-21 2022-05-05 Boehringer Ingelheim Vetmedica Gmbh Formulación farmacéutica que comprende ciclesonida
LT3157522T (lt) 2014-06-18 2019-11-25 Boehringer Ingelheim Vetmedica Gmbh Muskarininiai antagonistai ir jų deriniai, skirti arklių kvėpavimo takų ligos gydymui
EP3432954B1 (en) * 2016-03-24 2022-04-20 Services Medicaux Arnold et Joan Zidulka Inc. Device for delivering particles in the upper respiratory tract
MX382216B (es) 2016-06-02 2025-03-13 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CN111417410B (zh) 2017-12-01 2023-06-23 艾伯维公司 糖皮质激素受体激动剂及其免疫缀合物
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039123B1 (en) * 1980-02-27 1984-10-03 TATE & LYLE PUBLIC LIMITED COMPANY Crystalline glucose and process for its production
US4816445A (en) * 1984-06-21 1989-03-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Crystalline alpha-maltose
JP2518646B2 (ja) * 1987-05-29 1996-07-24 株式会社 林原生物化学研究所 マルト−ス粉末の製造方法
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE69012458T3 (de) 1989-05-31 2000-01-20 Fisons Plc, Ipswich Medikament und Inhalationsvorrichtung dafür.
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US6536427B2 (en) * 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
JPH05505824A (ja) 1990-03-23 1993-08-26 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5434304A (en) * 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
DE69105212T2 (de) 1990-10-18 1995-03-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzubereitung, die beclometason 17,21-dipropionat enthält.
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6866839B2 (en) * 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
NZ243061A (en) * 1991-06-10 1993-09-27 Schering Corp Aerosol containing a medicament and 1,1,1,2,3,3,3-heptafluoropropane
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9213874D0 (en) 1992-06-30 1992-08-12 Fisons Plc Process to novel medicament form
GB9306703D0 (en) 1993-03-31 1993-05-26 Fisons Plc Inhalation device
SK281226B6 (sk) * 1993-04-02 2001-01-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Prednizolónové deriváty, liečivá s ich obsahom a ich použitie
US5476411A (en) 1993-07-16 1995-12-19 Henkel Corporation Aqueous composition for wet sanding of dried paint, plastics, and the like
IL111194A (en) 1993-10-08 1998-02-08 Fisons Plc Process for the production of medicament formulations
DE4434629C1 (de) * 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
DE19541689A1 (de) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
AP979A (en) 1995-04-14 2001-06-28 Glaxo Wellcome Inc Metered dose imhaler for salmeterol.
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
EP0833622B8 (en) * 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
AU7095296A (en) * 1995-09-26 1997-04-17 Takeda Chemical Industries Ltd. Phosphorylamides, their preparation and use
DE19635498A1 (de) 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
US6599927B2 (en) * 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US20020111495A1 (en) * 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
GB2329939A (en) * 1997-06-26 1999-04-07 Glaxo Group Ltd Self-lubricating valve stem for aerosol containers
US6470894B2 (en) 1997-09-19 2002-10-29 Thione International, Inc. Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
EP1054004B1 (en) * 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
SE9801368D0 (sv) 1998-04-20 1998-04-20 Astra Ab New use
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6264923B1 (en) * 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
DE59911149D1 (de) * 1998-07-24 2004-12-30 Jago Res Ag Muttenz Medizinische aerosolformulierungen
AU749697B2 (en) 1998-08-04 2002-07-04 Jagotec Ag Medicinal aerosol formulations
CZ292335B6 (cs) 1998-09-23 2003-09-17 Altana Pharma Ag Tetrahydropyridoethery, jejich použití a farmaceutický prostředek
ATE382386T1 (de) * 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6397838B1 (en) * 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
US6124268A (en) * 1999-02-17 2000-09-26 Natreon Inc. Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof
AU777167B2 (en) * 1999-04-23 2004-10-07 Battelle Memorial Institute Directionally controlled EHD aerosol sprayer
ATE336301T1 (de) * 1999-04-23 2006-09-15 Ventaira Pharmaceuticals Inc Elektrostatisches versprühen mit transfer- hoher masse
JP2001048807A (ja) 1999-08-04 2001-02-20 Wakamoto Pharmaceut Co Ltd 難溶性薬物を水に溶解してなる製剤
DE19947234A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AR026072A1 (es) * 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0009607D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
FI20002177A0 (fi) 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
JP5021149B2 (ja) 2000-10-09 2012-09-05 スリーエム イノベイティブ プロパティズ カンパニー 医療用エアロゾル調合物
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2002038155A1 (en) * 2000-11-07 2002-05-16 Merck & Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
KR100881258B1 (ko) * 2000-12-22 2009-02-05 글락소 그룹 리미티드 살메테롤 지나포에이트를 위한 정량식 흡입기
WO2003006310A1 (fr) 2001-07-13 2003-01-23 Tfe Techniques Et Fabrications Electroniques Dispositif destine a indiquer acoustiquement a un plongeur equipe d'un scaphandre la pression de gaz de respiration dans le reservoir et/ou la pression hydrostatique
RU2279292C2 (ru) * 2001-10-24 2006-07-10 Пари Гмбх Набор для приготовления фармацевтической композиции
HRP20040432A2 (en) 2001-11-17 2004-10-31 Aventis Pharma Ltd Adsorbents and uses thereof
CA2467652A1 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
CN100366256C (zh) * 2002-07-02 2008-02-06 奥坦纳医药公司 含有环索奈德的无菌水性混悬剂
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
ES2452691T5 (es) 2003-09-16 2022-09-14 Covis Pharma Gmbh Uso de ciclesonida para el tratamiento de enfermedades respiratorias

Also Published As

Publication number Publication date
JP5618452B2 (ja) 2014-11-05
US20070025923A1 (en) 2007-02-01
PT1670482E (pt) 2014-03-12
US20130143849A1 (en) 2013-06-06
US8371292B2 (en) 2013-02-12
CA2538419C (en) 2012-07-03
AU2004271744A1 (en) 2005-03-24
JP2012197306A (ja) 2012-10-18
EP1670482B1 (en) 2013-12-25
DK1670482T4 (da) 2022-08-22
HRP20140257T1 (hr) 2014-04-25
ES2452691T5 (es) 2022-09-14
AU2004271744B2 (en) 2010-07-29
EP1670482A1 (en) 2006-06-21
PL1670482T5 (pl) 2022-10-03
EP1670482B2 (en) 2022-06-29
CA2538419A1 (en) 2005-03-24
US20190290661A1 (en) 2019-09-26
US20220241297A1 (en) 2022-08-04
DK1670482T3 (en) 2014-03-17
JP2007505829A (ja) 2007-03-15
PL1670482T3 (pl) 2014-05-30
ES2452691T3 (es) 2014-04-02
WO2005025578A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
HRP20140257T4 (hr) Uporaba ciklesonida za liječenje bolesti dišnih puteva
Szefler Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid
ES2284732T3 (es) Derivados de indanilo para tratar enfermedades de las vias respiratorias.
Edsbäcker et al. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?
NO328698B1 (no) Anvendelse av mometasonfuroat for fremstilling av et torrpulverinhaleringsmedikament for behandling av sykdommer i de ovre eller nedre luftveier eller lunger
NZ541997A (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with a corticosteroid
KR19990071975A (ko) 신규한복합조성물
CN107998109A (zh) 药物组合物
US20090022671A1 (en) Treatment methods
JP2007505829A5 (cg-RX-API-DMAC7.html)
SK284252B6 (sk) Použitie inhibítora H+, K+ -ATPáz a glukokortikoidu v terapii a farmaceutická kompozícia s ich obsahom
Edsbäcker Pharmacological factors that influence the choice of inhaled corticosteroids
Mealy et al. Ciclesonide
Berger et al. The use of inhaled corticosteroids for persistent asthma in infants and young children
Pavord et al. Pharmacokinetic optimisation of inhaled steroid therapy in asthma
ES2356946T3 (es) Combinación de esteroides que tienen actividad corticosteroidea mejorada por transportadores.
JP2007533706A5 (cg-RX-API-DMAC7.html)
WO2001012191A2 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid
Williams Corticosteroid aerosols for the treatment of asthma
ES2365533T3 (es) Combinación de andolast / glucocorticoides.
Catherin et al. SAFETY, EFFICACY AND MANAGEMENT OF ASTHMA WITH ICS/LABA THERAPY: A REVIEW
Kemp Expected characteristics of an ideal, all-purpose inhaled corticosteroid for the treatment of asthma
CN113456618A (zh) 一种复方双嘧达莫的吸入制剂及其制备方法
Maxwell et al. Beclomethasone Dipropionate
JP2013056925A (ja) アンドラスト／グルココルチコイドの併用